Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D

OBJECTIVE
To evaluate the efficacy and safety of ultra rapid lispro (URLi) versus lispro in patients with type 2 diabetes on a basal-bolus insulin regimen.

RESEARCH DESIGN AND METHODS
This was a phase 3, treat-to-target, double-blind 26-week study. After an 8-week lead-in to optimize basal insulin glargine or degludec in combination with prandial lispro treatment, patients were randomized to blinded URLi (n = 336) or lispro (n = 337) injected 0–2 min prior to meals. Patients could continue metformin and or a sodium–glucose cotransporter 2 inhibitor. The primary end point was change in HbA1c from baseline to 26 weeks (noninferiority margin 0.4%), with multiplicity-adjusted objectives for postprandial glucose (PPG) excursions during a standardized meal test.

RESULTS
HbA1c improved for both URLi and lispro, and noninferiority was confirmed: estimated treatment difference (ETD) 0.06% (95% CI −0.05; 0.16). Mean change in HbA1c was −0.38% for URLi and −0.43% for lispro, with an end-of-treatment HbA1c of 6.92% and 6.86%, respectively. URLi was superior to lispro in controlling 1- and 2-h PPG excursions: 1-h ETD, −0.66 mmol/L (95% CI −1.01, −0.30); 2-h ETD, −0.96 mmol/L (−1.41, −0.52). Significantly lower PPG excursions were evident from 0.5 to 4.0 h postmeal with URLi treatment. There were no significant treatment differences in rates of severe or documented hypoglycemia (<3.0 mmol/L). Incidence of overall treatment-emergent adverse events was similar between treatments.

CONCLUSIONS
URLi compared with lispro in a basal-bolus regimen was confirmed to be noninferior for HbA1c and superior to lispro for PPG control in patients with type 2 diabetes.

There have been many advances in the treatment of type 2 diabetes; however, reaching glycemic goals remains a challenge. Only ~30% of patients with type 2 diabetes are able to attain an HbA1c target of <7% even with insulin therapy (1). The overall proportion of patients reaching HbA1c <7% or individualized HbA1c targets has not improved during the past decade (2). HbA1c provides an integrated
Ultra rapid lispro (URLi) is a novel ultra rapid insulin lispro formulation developed to more closely match physiological insulin secretion, with the goal of improving PPG control. It uses two excipients to accelerate the absorption of insulin lispro at the injection site: a microdose of treprostinil, a prostacyclin analog, which increases local vasodilation, and citrate, which enhances local vascular permeability (10,11). In a phase 1 study comparing the pharmacokinetics and pharmacodynamics of URLi to lispro (Humalog) with a euglycemic clamp in patients with type 2 diabetes, the onset of appearance of insulin lispro in serum was 5 min faster with URLi, resulting in a sixfold higher insulin exposure in the first 15 min after injection (12). In addition, the duration of exposure was reduced by 51 min with URLi treatment. A corresponding shift was observed in the pharmacodynamic profile. A fourfold increase in the amount of glucose infused within the first 30 min and a 19% reduction in insulin action from 4 h to the end of the clamp were observed with URLi compared with lispro.

The aim of this study was to demonstrate that glycemic control with URLi is noninferior to lispro as measured by the change from baseline to week 26 in HbA1c in patients with type 2 diabetes when administered subcutaneously as part of a basal-bolus regimen.

RESEARCH DESIGN AND METHODS

This phase 3, double-blind, treat-to-target, 26-week, multicenter, multinational, randomized, controlled, parallel-design trial (Supplementary Fig. 1) was approved by local ethics review boards and conducted in accordance with the Good Clinical Practice of the International Conference on Harmonization Guideline (13). All patients provided written informed consent.

Participants

Adults with type 2 diabetes and an HbA1c between 7.0% (53.0 mmol/mol) and 10.0% (85.8 mmol/mol) inclusive were eligible for inclusion in the trial. Eligible participants had been treated for ≥90 days with basal insulin in combination with one or more prandial injections of bolus insulin per day or premixed insulin at least twice daily. In addition, they may have been treated with up to three oral antihyperglycemic medications (OADs) with stable dosing for ≥90 days prior to screening. (Additional inclusion/exclusion criteria are listed in Supplementary Table 1). Investigators at 131 study centers and 15 countries participated in the study (Supplementary Table 7).

Study Design and Treatment

Following a 1-week screening period, patients entered an 8-week lead-in period focusing on basal insulin optimization. Patients were treated with basal insulin glargine U100 once or twice daily or insulin degludec U100 or U200 once daily as determined by the investigator and three prandial injections per day of insulin lispro. Patients could continue metformin and/or a sodium–glucose co-transporter 2 inhibitor during the study but were required to discontinue all other OADs at the beginning of the lead-in. Basal insulin was titrated to a fasting blood glucose (FBG) target of 4.4–6.1 mmol/L during the lead-in period (Supplementary Table 2).

After the lead-in, patients were randomized 1:1 to either double-blind URLi U100 or lispro U100, administered by blinded prefilled insulin pens 0–2 min prior to the start of each meal. Patients continued treatment with basal insulin glargine or degludec. Assignment to treatment groups was determined by a computer-generated random sequence using an interactive web response system and stratified by country, HbA1c stratum (≤8.0% or >8.0% at 1 week prior to randomization), type of basal insulin, and number of prestudy prandial insulin injections (<3 or ≥3/day). During the initial 12 weeks after randomization, study prandial insulin doses were adjusted in a treat-to-target manner to self-monitored blood glucose (SMBG) levels of 4.4–6.1 mmol/L fasting or pre-meal, 5.0–7.2 mmol/L bedtime, and ≤7.8 mmol/L 1–2 h postmeal. Insulin dosing was assessed at least weekly for 12 weeks and thereafter at each visit or more often as needed. Recommended basal and prandial insulin titration algorithms (Supplementary Table 2) were included in the protocols and could be adjusted by investigators for individual patient considerations. Basal insulin could be titrated as needed to facilitate optimal prandial dosing or for safety reasons. Patients then entered a 14-week maintenance period from weeks 12–26 during which basal and prandial insulin doses could be adjusted to maintain glycemic control or for safety reasons.

A 4-h standardized liquid meal test (Ensure Plus, or a similar country option, with nutrient composition of ~700 calories, 100 g carbohydrate, 22 g fat, and 26 g protein) was performed at baseline (all patients on lispro) and week 26 (patients on blinded study insulin lispro or URLi) to assess PPG levels. Patients were required to have FBG in the range of 3.9–10.0 mmol/L, and the meal was to be consumed within 15 min. Serum glucose measurements were collected at time −15, 0, 15, 30, 60, 120, 180, and 240 min after the start of the meal. The prandial insulin dose administered during the meal test was individualized for each patient based on the carbohydrate content of the test meal and the patient’s insulin-to-carbohydrate ratio calculated from the average total daily insulin dose.

Patients performed 10-point SMBG profiles prior to scheduled visits at the following time points: fasting (morning premeal), prior to midday/evening meals, 1- and 2-h post–morning/midday/evening meals, and at bedtime. Patients were also instructed to take a minimum of four SMBG readings daily, with additional SMBG readings as needed for diabetes management and whenever hypoglycemia was suspected. Documented hypoglycemia was defined as measured SMBG <3.0 mmol/L. Nocturnal hypoglycemia was documented hypoglycemia occurring between bedtime and waking. Severe hypoglycemia was determined by the investigator as an episode requiring assistance of another
person due to neurological impairment and was reported as a serious adverse event per protocol.

**Sample Size and Statistical Analyses**
A total of 670 randomized patients would provide 99% statistical power to demonstrate noninferiority of URLi to lispro for change in HbA1c from 0 to 26 weeks with assumptions of no difference between treatment, an SD of 1.1%, at two-sided α-level 0.05, and 15% dropout rate in 26 weeks.

The primary efficacy measure was non-inferiority of URLi to lispro for HbA1c change from baseline to 26 weeks. URLi was declared noninferior to lispro if the upper limit of the two-sided 95% CI for the least squares mean (LSM) difference (URLi – lispro) for the change from baseline in HbA1c was < −0.4% (i.e., non-inferiority margin 0.4% [4.4 mmol/mol]). Two primary analysis methods were employed: 1) the efficacy estimand using the data prior to permanent discontinuation of study insulin and a mixed-effect model for repeated measures (MMRM) analysis; 2) the intention-to-treat estimand using all data from randomization through week 26 regardless of study insulin use, with multiple imputations for missing end points and an ANCOVA model. The MMRM model included treatment, strata (pooled country, type of basal insulin, and number of prandial doses at study entry), visit, and treatment-by-visit interaction as the fixed effects and baseline HbA1c as a covariate. The ANCOVA model included treatment and strata (pooled country, type of basal insulin, and number of prandial doses at study entry) as fixed effects and baseline HbA1c as a covariate.

A graphical approach (14) was used to strongly control the overall type I error of 0.05 for testing the treatment effect for the primary and the following key multiplicity-adjusted objectives: superiority of URLi compared to lispro for 1- and 2-h PPG excursion from the meal test at week 26 and change from baseline to week 26 in HbA1c (Supplementary Fig. 3).

ANCOVA was used to analyze the 1- and 2-h PPG excursions. The model included terms of strata (pooled country, type of basal insulin, number of prandial doses at study entry, and HbA1c stratum), treatment, and baseline. The superiority testing on change from baseline in HbA1c was assessed by the same analysis used for the primary objective. Additional continuous efficacy variables, as well as the change from baseline for these variables, were analyzed similarly either by the MMRM or ANCOVA models. For repeated binary measurements, a longitudinal logistic regression model was used for treatment comparison. The rate of severe hypoglycemia was analyzed using an empirical method, and other hypoglycemia event rates were analyzed by a negative binomial regression model. MMRM or ANCOVA model was used for other continuous variables.

**RESULTS**
Overall, 673 patients were randomized to URLi (n = 336) and lispro (n = 337). Patient disposition was similar between groups: 636 patients (95%) (n = 317, URLi; n = 319, lispro) completed 26 weeks of study treatment (Supplementary Fig. 2). Demographic and baseline characteristics were similar between groups (Table 1).

**Efficacy**

**HbA1c**
Mean HbA1c improved during the 8-week lead-in period in both groups from 8.3% (67.2 mmol/mol) to 7.3% (56.3 mmol/mol). After 26 weeks of treatment with URLi or lispro, there was further improvement in mean HbA1c to ~6.9% (51.9 mmol/mol) in both groups (Fig. 1). The mean change from baseline to week 26 was −0.38% (−4.1 mmol/mol) for URLi and −0.43% (−4.7 mmol/mol) for lispro, with an LSM difference (URLi – lispro) of 0.06% (95% CI −0.05 to 0.16) (−0.6 mmol/mol [95% CI −0.6 to 1.8]), confirming noninferiority of URLi to lispro (Fig. 1). Similar results were observed for the intention-to-treat estimand with an LSM difference of 0.03% (95% CI −0.08 to 0.13) (0.3 mmol/mol [95% CI −0.8 to 1.4 mmol/mol]). The multiplicity-adjusted objective for superiority of URLi to lispro in change from baseline to week 26 in HbA1c was not achieved for both analyses. At week 26, 58% of patients in the URLi group and 53% of patients in the lispro group reached target HbA1c < 7.0%, and 38% and 35%, respectively, achieved an HbA1c = 6.5%.

**Meal Test at Week 26**
PPG excursions during the standardized meal test at week 26 are shown in Fig. 2 (and Supplementary Table 3). URLi was superior to lispro in controlling 1- and 2-h PPG excursions, meeting the first and second multiplicity-adjusted objectives. Estimated change from baseline in PPG excursions was −0.77 mmol/L with URLi vs. −0.11 mmol/L with lispro at 1 h and −1.06 vs. −0.09 mmol/L, respectively, at 2 h postmeal. Mean PPG excursions were significantly lower in the URLi group compared with the lispro group at all time points from 30 min to 4 h (Supplementary Table 3).

Fasting glucose during the meal test was similar between groups (URLi, 7.17 mmol/L, and lispro, 6.98 mmol/L; P = 0.198), and mean PPG levels were significantly lower with URLi compared with lispro at all time points from 1 to 4 h (Supplementary Table 3). Incremental area under the serum glucose concentration time curve during the meal test was statistically significantly lower in the URLi group versus the lispro group at all time intervals during the 4-h test at week 26 (Supplementary Table 3). In addition, maximum glucose after the meal was significantly lower in the URLi group versus the lispro group (12.98 vs. 13.56 mmol/L, respectively; P = 0.015). Mean insulin dose with the meal test was similar between groups (URLi, 0.19 units/kg, and lispro, 0.18 units/kg).

**SMBG Profile**
At week 26, with 10-point SMBG profile testing, fasting glucose was similar between treatment groups with lower values observed with URLi compared with lispro for the morning 1-h postmeal (9.35 vs. 10.02 mmol/L respectively; P < 0.001) and 2-h postmeal (8.54 vs. 9.40 mmol/L respectively; P < 0.001) time points (Fig. 3). There were no statistically significant differences between groups at other time points. Overall daily mean glucose values from 10-point SMBG profiles at week 26 were not significantly different between groups (URLi, 8.84 mmol/L, and lispro, 9.01 mmol/L; P = 0.185) (Supplementary Table 6). However, daily mean PPG values were significantly lower with URLi compared with lispro at 1 h (9.23 vs. 9.60 mmol/L; P = 0.010) and at 2 h postmeal (8.86 vs.
Mean total daily insulin dose increased from 0.99 units/kg at baseline to 1.13 units/kg at week 26 for URLi and from 0.94 to 1.08 units/kg for lispro with no statistically significant difference between groups (Supplementary Table 4). Basal and bolus insulin doses (units/kg) were not statistically significantly different between groups at baseline or at week 26 (Supplementary Table 4). The ratio of prandial to total insulin dose at week 26 was similar between groups (URLi, 49.7%; lispro, 48.5%).

**Safety**

The incidence of severe hypoglycemia was low, with six patients (1.8%) reporting seven episodes in the lispro group and three patients (0.9%) reporting four episodes in the URLi group over 26 weeks of treatment (P = 0.350). There were no statistically significant differences in the rates of severe hypoglycemia, documented hypoglycemia (SMBG <3.0 mmol/L), or nocturnal hypoglycemia between groups (Table 2). The rate of postmeal hypoglycemia (SMBG <3.0 mmol/L) 0–1, 0–2, and >4 h after the meal was not significantly different between groups (Table 2). There was a statistically significantly higher rate of postmeal hypoglycemia with URLi compared with lispro treatment 0–4 h after the meal (Table 2).

Three deaths occurred during the study: 2 (0.6%) in the URLi group (acute myocardial infarction and septic shock) and 1 (0.3%) in the lispro group (sudden death). The incidence of serious adverse events, discontinuations from the study because of an adverse event, and treatment-emergent adverse events (TEAEs) was similar across treatment groups (Supplementary Table 5). Severe hypoglycemia was the most frequently reported serious adverse event. A small number of injection site reaction TEAEs was reported in this trial. Nine patients (2.7%) in the URLi group experienced a total of 10 injection site reaction TEAEs versus none in the lispro group (P = 0.002). The most common event was injection site pain (n = 5, 1.5%). All events were reported as of mild (n = 7) or moderate (n = 3) severity, and one patient discontinued study treatment because of an injection site reaction TEAE (injection site edema).

Weight increased with both treatments during the study with no significant

### Table 1—Baseline characteristics

| Characteristic                        | Lispro, N = 337 | URLi, N = 336 | Overall, N = 673 |
|---------------------------------------|----------------|--------------|-----------------|
| Age (years), mean ± SD                | 61.0 ± 9.2     | 60.2 ± 9.4   | 60.6 ± 9.3      |
| Women/men, %                          | 48.1/51.9      | 45.2/54.8    | 46.7/53.3       |
| **Race, n (%)**                       |                |              |                 |
| American Indian or Alaska Native      | 3 (0.9)        | 1 (0.3)      | 4 (0.6)         |
| Asian                                 | 81 (24.0)      | 83 (24.7)    | 164 (24.4)      |
| Black or African American             | 16 (4.7)       | 14 (4.2)     | 30 (4.5)        |
| Multiple                              | 6 (1.8)        | 5 (1.5)      | 11 (1.6)        |
| Native Hawaiian or other Pacific Islander | 1 (0.3)    | 0 (0.0)      | 1 (0.1)         |
| White                                 | 229 (68.0)     | 233 (69.3)   | 462 (68.6)      |
| Hispanic or Latino, n (%)             | 78 (23.1)      | 79 (23.5)    | 157 (23.3)      |
| Weight (kg), mean ± SD                | 90.0 ± 20.0    | 89.8 ± 20.5  | 89.9 ± 20.2     |
| BMI (kg/m²), mean ± SD                | 32.4 ± 5.8     | 32.1 ± 5.7   | 32.3 ± 5.7      |
| Duration of diabetes (years), mean ± SD | 16.6 ± 7.9   | 16.4 ± 7.8   | 16.5 ± 7.8      |
| Number of prestudy bolus injections, n (%) |               |              |                 |
| <3/day                                | 85 (25.2)      | 83 (24.7)    | 168 (25.0)      |
| ≥3/day                                | 252 (74.8)     | 253 (75.3)   | 505 (75.0)      |
| Basal insulin during study, n (%)     |                |              |                 |
| Insulin glargine                      | 257 (76.3)     | 260 (77.4)   | 517 (76.8)      |
| Insulin degludec                      | 80 (23.7)      | 76 (22.6)    | 156 (23.2)      |
| OAM use during study, n (%)           |                |              |                 |
| Metformin                             | 231 (68.5)     | 244 (72.6)   | 475 (70.6)      |
| SGLT2 inhibitor                       | 54 (16.0)      | 65 (19.3)    | 119 (17.7)      |
| HbA₁c, at study entry, mean ± SD      |                |              |                 |
| %                                     | 8.30 ± 0.75    | 8.30 ± 0.79  | 8.30 ± 0.77     |
| mmol/mol                              | 67.2 ± 8.3     | 67.2 ± 8.6   | 67.2 ± 8.4      |
| HbA₁c, at randomization, mean ± SD    |                |              |                 |
| %                                     | 7.31 ± 0.72    | 7.27 ± 0.68  | 7.29 ± 0.70     |
| mmol/mol                              | 56.4 ± 7.9     | 56.0 ± 7.5   | 56.2 ± 7.7      |

SGLT2, sodium–glucose cotransporter 2.

9.25 mmol/L; P = 0.013). Daily mean PPG excursions were also significantly lower with URLi from premeal to 1 and 2 h postmeal with a treatment difference (URLi–lispro) of −0.51 mmol/L at 1 h and −0.54 mmol/L at 2 h (all P < 0.001) (Supplementary Table 6).

**Other Efficacy Measures**

From baseline to week 26, 1,5-anhydroglucitol increased (improved) in both treatment groups (LSM change from baseline to week 26: URLi, increase of 1.99 mg/L; lispro, increase of 2.15 mg/L) with no difference between groups.

---

**Figure 1**—Mean HbA₁c during study lead-in and 26-week treatment. Data are mean at screening and LSM ± SE for all other time points.
difference between groups (1.4 kg with URLi vs. 1.6 kg with lispro; \( P = 0.350 \)). There were no clinically meaningful changes in laboratory assessments, blood pressure, or pulse in either treatment group.

CONCLUSIONS

In this double-blind, treat-to-target study of patients with type 2 diabetes, basal-bolus treatment with URLi compared with lispro met the primary objective of noninferiority of HbA1c change over 26 weeks of treatment. This is consistent with previous treat-to-target trials where noninferiority of HbA1c was demonstrated with novel insulins when they were compared with currently available insulin treatment options including fast-acting insulin aspart versus insulin aspart (15), insulin glargine versus NPH (16,17), insulin degludec versus insulin glargine (18), and in a systematic review of treat-to-target trials in patients with type 2 diabetes (17). Treat-to-target trial designs are commonly used to compare a new insulin with a currently available formulation. In these trials, insulin is titrated in both treatment groups based on the same prespecified glycemic targets. Similar changes in HbA1c between treatment groups allow for comparison of other efficacy and safety end points in order to better establish the risk-benefit profile of the new insulin (17). Treat-to-target trials are further strengthened when treatment groups are blinded, as in the current study.

HbA1c significantly improved in both treatment groups including during the 8-week basal optimization lead-in period from a mean of 8.3% at screening to 7.3% at the end of lead-in with basal-bolus treatment using lispro. With 26 weeks of blinded study treatment with URLi or lispro, glycemic control improved further in both groups, with achievement of overall good glycemic control and mean end point HbA1c of 6.9%.

URLi demonstrated superiority over lispro in controlling both 1- and 2-h PPG excursions during the standardized meal test at week 26, meeting the prespecified objectives. URLi significantly reduced the 1-h PPG excursion by 0.66 mmol/L and the 2-h PPG excursion by 0.96 mmol/L compared with lispro. Additionally, URLi treatment resulted in significantly lower PPG excursions starting at 30 min to over the 4-h duration of the meal test, with similar insulin dosing. The reductions in PPG excursions with URLi approach what were reported in studies of rapid-acting insulin analogs compared with human regular insulin (19,20). Studies of fast-acting insulin aspart in basal-bolus regimens with either insulin glargine or degludec in patients with type 2 diabetes have also demonstrated noninferiority of HbA1c (15,21). These studies resulted in a statistically significant reduction in the 1-h PPG excursion of 0.59 and 0.40 mmol/L with fast-acting insulin aspart versus insulin aspart but no treatment difference at the 2-h time point after a liquid meal test (15,21). In addition, in a clinical pharmacology study in patients with type 1 diabetes, URLi demonstrated statistically significant improvement in PPG excursions compared with insulin lispro and insulin aspart and numerically greater improvement compared

Figure 2—PPG excursions at week 26 with meal test. *\( P < 0.05 \) for between-treatment comparison; **\( P < 0.001 \) for between-treatment comparison. Data are LSM ± SE.

Figure 3—Ten-point SMBG profile at week 26. *\( P < 0.05 \) for between-treatment comparison. Data are LSM ± SE.
with fast-acting insulin aspart in response to a liquid meal test (22).

Supportive of the meal test results, 10-point SMBG testing demonstrated improved PPG control with significantly lower PPG levels after the morning meal and reduced daily mean PPG levels and daily mean PPG excursions with URLi compared with lispro. PPG treatment differences may not have been as evident with other meals, as the morning meal may be the most standardized, particularly in a large global study, and because glucose levels were already under reasonable control in both treatment groups at baseline after the lead-in period, with mean HbA1c of 7.3%. Insulin dose (units/kg) and the ratio of prandial to total insulin were not significantly different between treatment groups at 48–50%. The overall pattern of glucose levels increased after the midday meal and thereafter remained stable until bedtime. It is possible that a higher percentage of bolus compared with basal insulin, with higher prandial insulin dosing with the midday and evening meals, may further improve glycemic control and PPG. One could also speculate that adjustment of basal insulin dosing may be needed to further optimize glycemic control and PPG control throughout the entire day with URLi and other next-generation ultra rapid insulin analogs (23). Despite these considerations, good glycemic control with an end point mean HbA1c of <7% was achieved with URLi and lispro, with similar rates of overall hypoglycemia. Further evaluation and potential optimization of basal/bolus dosing for individual patients with use of URLi in studies as well as in real-life settings and in clinical practice would be of interest.

In patients with longer duration of type 2 diabetes, as in the PRONTO-T2D study, management of postprandial hyperglycemia remains the primary unmet need, with a significant number of patients not meeting glycemic goals despite treatment with multiple agents as well as basal insulin (24). Therapeutic interventions to decrease PPG excursions may be as important as or more important than fasting glucose in reaching overall glycemic goals and in decreasing the risk of diabetes and cardiovascular complications (25,26). Epidemiology studies have shown the increased risk of cardiovascular disease and mortality associated with elevated PPG levels (27–30).

Improved glycemic control was achieved with no statistically or clinically significant differences in the most clinically relevant categories of hypoglycemia, including severe hypoglycemia, documented hypoglycemia <3.0 mmol/L, and nocturnal hypoglycemia. The incidence of severe hypoglycemia was low despite achievement of good glycemic control. Postmeal hypoglycemia rates were statistically significantly higher in URLi-treated patients within 4 h of the meal; however, the absolute rates were very low, corresponding to less than one additional event per patient-year. Postmeal hypoglycemia rates were similar between treatment groups >4 h postmeal. These findings are also overall consistent with the increased postmeal rate of hypoglycemia 0–2 h after meals with fast-acting insulin aspart compared with insulin aspart (15). Consistent with the faster time-action profile of URLi and of ultra rapid bolus insulin formulations in general, these data are suggestive of a trend toward earlier hypoglycemic events (but importantly no difference in overall hypoglycemia) with URLi compared with lispro.

The safety profile and overall frequency of treatment-emergent adverse events between treatments were similar between groups. As with any insulin treatment, injection site reactions (of primarily mild severity) were reported with URLi treatment; however, the incidence was low (~2.7%) and overall similar to that previously reported for other insulins such as fast-acting insulin aspart (1.6%) (31) and insulin glargine (2.7%) (32).

Strengths of this study include the double-blind design, the high completion rate (>94%), and the global nature of the study including North/South America, Asia, Australia, and Europe. Although 10-point SMBG profiles provided data for diabetes management and for assessment of PPG in more of a real-life setting, continuous glucose monitoring (CGM) data were not obtained in the study. Blinded CGM data were obtained in a subset of patients with type 1 diabetes in the phase 3 PRONTO-T1D study and demonstrated improved PPG control and significantly increased time in range during the daytime period with URLi treatment versus lispro (33). For future directions, it would be of interest to obtain CGM data in patients with type 2 diabetes to further assess the effects of URLi treatment on glycemic control and outcomes beyond HbA1c such as time in target glucose range and to further evaluate PPG control and the 24-h ambulatory glucose profile. Study limitations include the use of a liquid meal test, which allowed standardization across multiple countries in a global study but

| Table 2—Summary of rates of hypoglycemia (baseline to week 26) |
|---------------------------------------------------------------|
| **Lispro, N = 337** | **URLi, N = 336** | **Relative rate URLi/lispro (95% CI)** |
| **Rate (events/patient/year)** | **Rate (events/patient/year)** | **** |
| Severe hypoglycemia | 0.04 | 0.02 | 0.58 (0.14, 2.50) |
| Documented hypoglycemia | 7.43 | 7.57 | 1.02 (0.81, 1.28) |
| Nocturnal hypoglycemia | 0.53 | 0.68 | 1.29 (0.82, 2.03) |
| Postmeal hypoglycemia (h) |
| 0–1 | 1.54 | 1.76 | 1.14 (0.75, 1.74) |
| 0–2 | 1.86 | 2.47 | 1.33 (0.92, 1.92) |
| 0–4 | 2.58 | 3.51* | 1.36 (1.01, 1.83)* |
| >4 | 1.15 | 1.10 | 0.95 (0.61, 1.48) |

Data are LSM unless otherwise stated. Hypoglycemia was defined as SMBG <3.0 mmol/L (54 mg/dL) for documented, nocturnal, and postmeal hypoglycemia. For postmeal hypoglycemia, patient reported timing in relation to meal. *P < 0.05 for between-treatment group comparisons.
may not fully represent a typical meal. Of note, URLU has been shown to reduce PPG excursions compared with lispro in clinical pharmacology studies with use of solid mixed-meal tolerance tests in patients with type 1 and type 2 diabetes (34,35). In addition, given the design with the lead-in period, patients overall had reasonably controlled diabetes at baseline prior to starting blinded study treatment. The study enrolled patients already treated with a component of basal-bolus therapy; it would also be of interest to evaluate URLU treatment in patients with type 2 diabetes new to bolus insulin therapy.

In conclusion, this 26-week, double-blind, treat-to-target study in patients with type 2 diabetes previously treated with insulin demonstrated that basal-bolus treatment with URLU compared with lispro provided good glycemic control, with clinically significant reductions in HbA1c and similar overall hypoglycemia. Furthermore, URLU in a basal-bolus regimen provided superior PPG control over lispro treatment in patients with type 2 diabetes.

Acknowledgments. The authors thank the study participants and the investigators and study coordinators who cared for them. The authors also thank Dr. Thomas Hardy and Mary Anne Delvia (Eli Lilly and Company, Indianapolis, IN) for critically reviewing the manuscript and Farai Chigutsa (Eli Lilly and Company, Indianapolis, IN) for medical writing and editorial assistance.

Duality of Interest. This study was funded by Eli Lilly and Company. T.B. has been on the speakers’ bureau for Abbott, Allergan, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Merck, Sanofi, and Sensionics and has received research support from Eli Lilly and Company, Medtronic, Mylan, and Novo Nordisk. Q.Z. and A.M.C. are employees and shareholders of Eli Lilly and Company. J.P.F. has been on the speakers’ bureau for Merck and Sanofi; has received research support from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Janssen, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, and Theracos; and is on the advisory board and is a consultant for Boehringer Ingelheim, Eli Lilly and Company, Gilead, Merck, Novo Nordisk, and Sanofi. No other potential conflicts of interest relevant to this article were reported.

Author Contributions. T.B., J.P.F., and H.J. participated as trial investigators and reviewed and edited the manuscript. Q.Z contributed to the study design, the statistical analyses, the interpretation of the research, writing the statistical methods, and reviewing and editing the manuscript. A.M.C. was responsible for medical oversight during the trial and contributed to the study design, the data analysis and interpretation of the research, and writing the manuscript. All authors approved the final manuscript to be published. A.M.C. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation. Parts of this study were presented in abstract form at the 79th Scientific Sessions of the American Diabetes Association, San Francisco, CA, 7–11 June 2019; the 46th Annual Meeting and Exhibition of the American Association of Diabetes Educators, Houston, TX, 9–12 August 2019; the 55th Annual Meeting of the European Association for the Study of Diabetes, 16–20 September 2019, Barcelona, Spain; the 7th Gulf Chapter Annual Meeting of the American Association of Clinical Endocrinologists, Muscat, Oman, 10–12 October 2019; and the 22nd National Congress of Associazione Medici Diabetologi, Padua, Italy, 27–30 November 2019.

References
1. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care 2013;36: 2271–2279
2. Carls G, Huyhn J, Tuttle E, Yee J, Edelman SV. Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Ther 2017;8:863–873
3. Bonora E, Tuomilehto J. The pros and cons of diagnosing diabetes with A1C. Diabetes Care 2011;34(Suppl. 2):S184–S190
4. Sherwani SI, Khan HA, Ekizaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark Insights 2016;11:95–104
5. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003; 26:881–885
6. Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough—what next? Diabetes Metab Res Rev 2007;23:257–264
7. Liebl A, Prager R, Binz K, Kaiser M, Bergental R, Gallwitz B; PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 2009;11:45–52
8. Rosenstock J, Ahmnn AJ, Colon G, Scism-Bacon B, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabete care 2008;31:20–25
9. Bergenthal RM, Peyrot M, Dreon DM, et al.; Calibra Study Group. Implementation of basal-bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen. Diabetes Technol Ther 2019;21:273–285
10. Pratt E, Leohr J, Heilmann C, Johnson J, Landschulz W. Treprostinil causes local vasodilation, is well tolerated, and results in faster absorption of insulin lispro (Abstract). Diabetes 2017;66: A253
11. Michael MD, Zhang C, Siesky AM, et al. Exploration of the mechanism of accelerated absorption for a novel insulin lispro formulation (Abstract). Diabetes 2017;66(Suppl. 1):A250
12. Leorh J, Delvia MA, Coutant D, et al. Ultra rapid lispro (URLU) accelerates insulin lispro absorption and insulin action vs. humalog (lispro) in rapid patients with T2D (Abstract). Diabetes 2019; 68(Suppl. 1):L100-P
13. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: Guidelines for Good Clinical Practice, 2016. Available from https://database.ich.org/sites/default/files/ E6_R2_Addendum.pdf. Accessed 7 October 2019
14. Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. Biom J 2011;53:894–913
15. Bowering K, Case C, Harvey J, et al. Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: the onset 2 trial. Diabetes Care 2017; 40:951–957
16. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26: 3080–3086
17. Garber AJ. Treat-to-target trials: uses, interpretation and review of concepts. Diabetes Obes Metab 2014;16:193–205
18. Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther 2014;5: 435–446
19. Rys P, Pankiewicz O, Lach K, Kwaskowski A, Skrzekowska-Baran I, Malecki MT. Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: a systematic review. Diabetes Metab 2011;37: 190–200
20. Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab 2012;14:780–788
21. Lane W, Bokurt K, Favaro E, Jang HC, Kjærsgaard MJS. Efficacy and safety of fast-acting insulin aspart compared with insulin aspart, both with insulin degludec with or without metformin, in adults with type 2 diabetes. Diabetologia 2019;62:510–51
22. Heise T, Linnebjerg H, Cao D, et al. Ultra rapid lispro (URLU) lowers postprandial glucose (PPG) and more closely matches normal physiological glucose response compared to other rapid insulin analogs (Abstract). Diabetes 2019;68(Suppl. 1): 1112-P
23. Owens DR, Bolli GB. The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications. Diabetes Obes Metab 2020;22:743–754
24. Riddle MC. Basal glucose can be controlled, but the prandial problem persists—it’s the next target! Diabetes Care 2017;40:291–300
25. Leahy JJL, Aleppo G, Fonseca VA, et al. Optimizing postprandial glucose management in adults with insulin-requiring diabetes: report and recommendations. J Endocr Soc 2019;3:1942–1957
26. Ceriello A, Genovese S. Atherogenicity of postprandial hyperglycemia and lipotoxicity. Rev Endocr Metab Disord 2016;17:111–116
27. Bonora E. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract Suppl 2002;129:5–11
28. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577–1583
29. Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91:813–819
30. Ceriello A, Davidson J, Hanefeld M, et al.; International Prandial Glucose Regulation Study Group. Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. Nutr Metab Cardiovasc Dis 2006;16:453–456
31. FIASP (insulin aspart) [package insert]. Bagsvaerd, Denmark, Novo Nordisk, 2017
32. Lantus (insulin glargine injection) [package insert]. Bridgewater, NJ, sanofi-aventis U.S. LLC, 2013
33. Bode BW, Cao D, Liu R, Hardy T, Bue-Valleskey J. Ultra rapid lispro (URLi) improves postprandial glucose (PPG) control and time in range (TIR) in T1D compared with humalog (lispro): PRONTO-T1D Continuous Glucose Monitoring (CGM) Substudy (Abstract). Diabetes 2019;68(Suppl.):1089-P
34. Plum-Möerschel L, Leohr J, Liu R, et al. Ultra-rapid lispro (URLi) reduces postprandial glucose excursions vs. humalog in patients with T1D at multiple meal-to-dose timing intervals (Abstract). Diabetes 2018;67(Suppl. 1):1010-P
35. Kapitza C, Leohr J, Liu R, et al. Ultra-rapid lispro (URLi) reduces postprandial glucose excursions vs. humalog in patients with T2D at multiple meal-to-dose timing intervals (Abstract). Diabetes 2018;67(Suppl. 1):1009-P